양춘사 추출물이 HT-29 세포에서 염증성 장 질환(IBD)에 미치는 항염증 효과
Anti-inflammatory Effects of Amomum Villosum Lour Extract on HT-29 Cells: Potential Therapeutic Applications for Inflammatory Bowel Diseases
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Amomum villosum Lour extract (AVE) has been traditionally known for its therapeutic properties. This study investigated the anti-inflammatory effects of AVE on HT-29 colon epithelial cells to evaluate its potential application for inflammatory bowel diseases (IBD). The MTT assay demonstrated that AVE did not induce cytotoxicity across a wide range of concentrations, confirming its safety for cell viability. Enzyme-linked immunosorbent assay (ELISA) revealed that AVE significantly reduced the secretion of inflammatory cytokines IL-8 and TNF-α, while MCP-1 levels decreased even at low concentrations (100 μg/ml) and remained consistently low at higher concentrations. RT-PCR and Western blot analyses further confirmed the suppression of inflammatory markers (iNOS, COX-2, TNF-α) and the upregulation of mucosal barrier proteins (ZO-1, Occludin). These findings suggest that AVE modulates LPS-induced inflammatory signaling pathways and enhances mucosal barrier integrity, highlighting its potential as a therapeutic agent for IBD.
Abstract
Amomum villosum Lour extract (AVE) has been traditionally known for its therapeutic properties. This study investigated the anti-inflammatory effects of AVE on HT-29 colon epithelial cells to evaluate its potential application for inflammatory bowel diseases (IBD). The MTT assay demonstrated that AVE did not induce cytotoxicity across a wide range of concentrations, confirming its safety for cell viability. Enzyme-linked immunosorbent assay (ELISA) revealed that AVE significantly reduced the secretion of inflammatory cytokines IL-8 and TNF-α, while MCP-1 levels decreased even at low concentrations (100 μg/ml) and remained consistently low at higher concentrations. RT-PCR and Western blot analyses further confirmed the suppression of inflammatory markers (iNOS, COX-2, TNF-α) and the upregulation of mucosal barrier proteins (ZO-1, Occludin). These findings suggest that AVE modulates LPS-induced inflammatory signaling pathways and enhances mucosal barrier integrity, highlighting its potential as a therapeutic agent for IBD.